降圧薬の世界市場レポート 2024

降圧薬の市場規模は、今後数年間で着実に成長すると予想されています。2028年には2.4%の年間複合成長率（CAGR）で402億8,000万米ドルに成長すると予想されます。予測期間中に予測される成長は、費用対効果と手頃な価格、治療革新の出現、疫学の動向、規制の変更と承認、高齢化に関連する力学、ヘルスケア政策と償還構造の変化などの要因に起因すると考えられます。予測期間中に予想される主な動向には、治療技術の革新、疫学パターンの変化、規制状況の変化、ヘルスケア政策の進化、診断とモニタリングの進歩が含まれます。

座りっぱなしのライフスタイルは、降圧薬市場の拡大を促進する重要な要因として際立っています。高血圧の上昇は、不健康なジャンクフードの摂取、バランスの取れた食事の不適切な遵守、型破りな勤務シフトによる不規則な睡眠パターンなどの要因に起因すると考えられます。これらのライフスタイル要素は高血圧の急増に寄与し、その結果、心臓病関連死亡の45%と脳卒中関連死亡の51%の主な前兆となります。2021年6月の世界保健機関（WHO）のデータによると、心血管疾患（CVD）は年間推定1,790万人の命を奪い、世界の主な死因となっています。降圧薬に対するこの持続的な需要は、市場の成長を促進する重要な促進力です。

心血管疾患の有病率の拡大は、降圧薬市場の将来の成長を促進すると予想されます。心血管疾患には、喫煙、高血圧、高コレステロール、糖尿病、肥満、座りっぱなしのライフスタイルなどの危険因子を含む、心臓と血管に影響を与えるさまざまな状態が含まれます。降圧薬は、高齢者の心血管疾患の主要な危険因子である高血圧の管理と軽減に重要な役割を果たします。2022年10月、国立医学図書館は、2035年までに米国人口の45.1%が心血管疾患を患い、総コストは1兆1,000億米ドルに達する可能性があると予測しました。さらに、世界心臓連盟の2023年5月のデータでは、2021年に心血管疾患による死亡者数が2,050万人であることが明らかになりました。その結果、心血管疾患の有病率の増加が降圧薬市場の拡大を推進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の降圧薬市場の促進要因と抑制要因
  • 市場の促進要因
  • 市場の抑制要因
• 世界の降圧薬市場規模実績と成長、2018年～2023年
• 世界の降圧薬市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の降圧薬市場、治療薬別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
• 利尿薬
• アンジオテンシン受容体遮断薬（ARB）
• アンジオテンシン変換酵素（ACE）阻害剤
• ベータブロッカー
• アルファブロッカー
• カルシウムチャネルブロッカー
• レニン阻害剤
• 血管拡張薬
• 世界の降圧薬市場、疾患原因別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
• 原発性高血圧症
• 二次性高血圧症
• 世界の降圧薬市場、エンドユーザー別のセグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
• 病院
• クリニック
• ホームケア

第7章 地域と国の分析

• 世界の降圧薬市場、地域別、実績と予測、2018年～2023年、2023年～2028年、2033年
• 世界の降圧薬市場、国別、実績と予測、2018年～2023年、2023年～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 降圧薬市場の競合情勢
• 降圧薬市場の企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson Ltd.
  • F. Hoffmann-La Roche Ltd
  • Merck &Co. Inc.
  • AbbiVe Inc.

第31章 その他の大手と革新的な企業

• Bayer AG
• Novartis AG
• Sanofi SA
• Astra Zeneca plc
• Abbott Laboratories
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• CH Boehringer Sohn AG &Ko. KG
• Teva Pharmaceutical Industries Ltd.
• Mylan NV
• Daiichi Sankyo Company Limited
• Fresenius Kabi AG
• Sun Pharmaceuticals LLC

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Anti-hypertensive drugs constitute a category of medications utilized in the treatment of high blood pressure (hypertension). The primary objective of antihypertensive therapy is to prevent the adverse effects associated with elevated blood pressure, such as myocardial infarction and stroke.

The key therapeutic classes of anti-hypertensive drugs include diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, alpha-blockers, calcium channel blockers, renin inhibitors, and vasodilators. Diuretics, commonly known as water pills, work by increasing the elimination of water and salt from the body through urine. Various sources of hypertension encompass primary and secondary hypertension, both of which are addressed through treatment modalities in hospitals, clinics, and home care settings.

The anti-hypertensive drugs market research report is one of a series of new reports from The Business Research Company that provides anti-hypertensive drugs market statistics, including anti-hypertensive drugs industry global market size, regional shares, competitors with an anti-hypertensive drugs market share, detailed anti-hypertensive drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-hypertensive drugs industry. This anti-hypertensive drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-hypertensive drugs market size has grown steadily in recent years. It will grow from $35.8 billion in 2023 to $36.7 billion in 2024 at a compound annual growth rate (CAGR) of 2.5%. The growth observed in the historical period can be attributed to influences stemming from environmental and lifestyle factors, historical market competition, prevailing treatment preferences in the past, economic conditions, and trends in global health history.

The anti-hypertensive drugs market size is expected to see steady growth in the next few years. It will grow to $40.28 billion in 2028 at a compound annual growth rate (CAGR) of 2.4%. The projected growth in the forecast period can be attributed to factors such as cost-effectiveness and affordability, the emergence of therapeutic innovations, trends in epidemiology, regulatory changes and approvals, dynamics related to an aging population, and shifts in healthcare policies and reimbursement structures. Key trends anticipated in the forecast period encompass therapeutic innovation, changes in epidemiological patterns, shifts in the regulatory landscape, evolving healthcare policies, and advancements in diagnosis and monitoring.

A sedentary lifestyle stands out as a significant catalyst for the expansion of the anti-hypertensive drug market. The rise in hypertension can be attributed to factors such as the consumption of unhealthy junk food, inadequate adherence to a balanced diet, and irregular sleep patterns resulting from unconventional work shifts. These lifestyle elements contribute to an upsurge in hypertension, which, in turn, serves as a major precursor for 45% of heart disease-related deaths and 51% of stroke-related fatalities. As per World Health Organization (WHO) data from June 2021, cardiovascular diseases (CVDs) claim an estimated 17.9 million lives annually, making them the leading global cause of death. This sustained demand for anti-hypertensive drugs is a key driver fostering market growth.

The escalating prevalence of cardiovascular diseases is expected to drive future growth in the anti-hypertensive drugs market. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, with risk factors including smoking, high blood pressure, high cholesterol, diabetes, obesity, and a sedentary lifestyle. Anti-hypertensive drugs play a crucial role in managing and mitigating high blood pressure, a major risk factor for cardiovascular diseases in older adults. In October 2022, the National Library of Medicine projected that by 2035, 45.1% of the US population could have cardiovascular disease, with total costs reaching $1.1 trillion. Additionally, data from the World Heart Federation in May 2023 revealed 20.5 million deaths from cardiovascular diseases in 2021. Consequently, the increasing prevalence of cardiovascular diseases is propelling the expansion of the anti-hypertensive drugs market.

One significant impediment to the anti-hypertensive drugs market is the low awareness of these medications among the population. In developing nations, many individuals neglect regular health checkups, often remaining unaware of their hypertension until severe symptoms manifest. Moreover, diagnosed individuals exhibit low adherence to prescribed medication schedules, frequently discontinuing treatment after 1-2 weeks, leading to significant challenges for the anti-hypertensive drugs market. A research survey published by BMC Research from a developing country highlighted that only 17% of 112 hypertensive subjects with stroke were adherent to antihypertensive medications. Hence, lack of awareness and poor drug adherence pose constraints to the growth of the anti-hypertensive market.

Prominent companies in the anti-hypertensive drugs market are concentrating their efforts on introducing innovative products, including Metoprolol Succinate Extended-Release Tablets, to gain a competitive advantage. Metoprolol Succinate Extended-Release Tablets serve as anti-hypertensive drugs tailored for patients with hypertension. For example, in June 2023, Granules India Limited, a pharmaceutical manufacturing company based in India, unveiled Metoprolol Succinate Extended-Release Tablets, which received approval from the US Food and Drug Administration (FDA). These tablets, available in strengths ranging from 25mg to 200mg, function as beta-blockers, slowing down the heart rate, easing the workload on the heart, and ultimately lowering blood pressure.

In recent times, there has been a notable surge in the adoption of combination therapies compared to monotherapy for hypertension treatment. While monotherapy involves using a single drug, combination therapy utilizes a mix of drugs to target various hypertensive mechanisms concurrently. Combining two drugs with distinct mechanisms of action results in an effect two to five times greater than monotherapy. Studies indicate that increasing the dose of monotherapy leads to a 29% reduction in coronary events and a 40% reduction in cerebrovascular events. In contrast, combining two antihypertensive agents with different mechanisms of action achieves a more significant impact, reducing coronary events by 40% and cerebrovascular events by 54%. Consequently, the trend of employing combination therapy is gaining widespread acceptance due to its enhanced effectiveness.

The US Food and Drug Administration (FDA) has issued guidance regarding the development of fixed-combination drugs for hypertension. This guidance primarily focuses on the clinical development of two-drug combinations comprising previously approved products. The FDA anticipates a decrease in adverse effects for combinations that include doses below each drug's maximum dose compared to single drug regimens at their maximum dose. Current medical guidelines recommend initiating patients on two drugs at less than their full doses, marking a departure from the earlier practice of starting with a single drug and titrating up to the maximum dose before introducing additional drugs. This guidance is expected to regulate the development of fixed-combination drugs for hypertension.

Major companies operating in the anti-hypertensive drugs market report are Pfizer Inc., Johnson & Johnson Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbiVe Inc., Bayer AG, Novartis AG, Sanofi SA, Astra Zeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., C.H. Boehringer Sohn AG & Ko. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Fresenius Kabi AG, Sun Pharmaceuticals LLC, Cipla Limited, Dr. Reddy's Laboratories, Hikma Pharmaceuticals PLC, Lupin Limited, United Therapeutics, Torrent Pharmaceuticals Ltd., Ranbaxy Laboratories, Noden Pharma DAC, Acacia Pharma Group PLC, Actelion Pharmaceuticals Ltd.

North America was the largest region in the anti-hypertensive drugs market in 2023. The Middle East is expected to be the largest growing region in the global anti-hypertensive drugs market during the forecast period. The regions covered in the anti-hypertensive drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the anti-hypertensive drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The anti-hypertensive drugs market consists of sales of thiazide-type diuretics, beta-blocker metoprolol, olmesartan, and HCTZ. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Hypertensive Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-hypertensive drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-hypertensive drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-hypertensive drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Therapeutics: Diuretics; Angiotensin Receptor Blockers (ARBs); Angiotensin Converting Enzyme (ACE) Inhibitors; Beta Blockers; Alpha Blockers; Calcium Channel Blockers; Renin Inhibitors; Vasodilators
• 2) By Disease Source: Primary Hypertension; Secondary Hypertension
• 3) By End Users: Hospitals; Clinics; Homecare
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Ltd.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbiVe Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anti-Hypertensive Drugs Market Characteristics

3. Anti-Hypertensive Drugs Market Trends And Strategies

4. Anti-Hypertensive Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Anti-Hypertensive Drugs Market Size and Growth

• 5.1. Global Anti-Hypertensive Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Anti-Hypertensive Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Anti-Hypertensive Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Anti-Hypertensive Drugs Market Segmentation

• 6.1. Global Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Diuretics
• Angiotensin Receptor Blockers (ARBs)
• Angiotensin Converting Enzyme (ACE) Inhibitors
• Beta Blockers
• Alpha Blockers
• Calcium Channel Blockers
• Renin Inhibitors
• Vasodilators
• 6.2. Global Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Primary Hypertension
• Secondary Hypertension
• 6.3. Global Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Homecare

7. Anti-Hypertensive Drugs Market Regional And Country Analysis

• 7.1. Global Anti-Hypertensive Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Anti-Hypertensive Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Anti-Hypertensive Drugs Market

• 8.1. Asia-Pacific Anti-Hypertensive Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Anti-Hypertensive Drugs Market

• 9.1. China Anti-Hypertensive Drugs Market Overview
• 9.2. China Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Anti-Hypertensive Drugs Market

• 10.1. India Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Anti-Hypertensive Drugs Market

• 11.1. Japan Anti-Hypertensive Drugs Market Overview
• 11.2. Japan Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Anti-Hypertensive Drugs Market

• 12.1. Australia Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Anti-Hypertensive Drugs Market

• 13.1. Indonesia Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Anti-Hypertensive Drugs Market

• 14.1. South Korea Anti-Hypertensive Drugs Market Overview
• 14.2. South Korea Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Anti-Hypertensive Drugs Market

• 15.1. Western Europe Anti-Hypertensive Drugs Market Overview
• 15.2. Western Europe Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Anti-Hypertensive Drugs Market

• 16.1. UK Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Anti-Hypertensive Drugs Market

• 17.1. Germany Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Anti-Hypertensive Drugs Market

• 18.1. France Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Anti-Hypertensive Drugs Market

• 19.1. Italy Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Anti-Hypertensive Drugs Market

• 20.1. Spain Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Anti-Hypertensive Drugs Market

• 21.1. Eastern Europe Anti-Hypertensive Drugs Market Overview
• 21.2. Eastern Europe Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Anti-Hypertensive Drugs Market

• 22.1. Russia Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Anti-Hypertensive Drugs Market

• 23.1. North America Anti-Hypertensive Drugs Market Overview
• 23.2. North America Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Anti-Hypertensive Drugs Market

• 24.1. USA Anti-Hypertensive Drugs Market Overview
• 24.2. USA Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Anti-Hypertensive Drugs Market

• 25.1. Canada Anti-Hypertensive Drugs Market Overview
• 25.2. Canada Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Anti-Hypertensive Drugs Market

• 26.1. South America Anti-Hypertensive Drugs Market Overview
• 26.2. South America Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Anti-Hypertensive Drugs Market

• 27.1. Brazil Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Anti-Hypertensive Drugs Market

• 28.1. Middle East Anti-Hypertensive Drugs Market Overview
• 28.2. Middle East Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Anti-Hypertensive Drugs Market

• 29.1. Africa Anti-Hypertensive Drugs Market Overview
• 29.2. Africa Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Anti-Hypertensive Drugs Market Competitive Landscape And Company Profiles

• 30.1. Anti-Hypertensive Drugs Market Competitive Landscape
• 30.2. Anti-Hypertensive Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche Ltd
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck & Co. Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AbbiVe Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Anti-Hypertensive Drugs Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Sanofi SA
• 31.4. Astra Zeneca plc
• 31.5. Abbott Laboratories
• 31.6. GlaxoSmithKline plc
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Eli Lilly and Company
• 31.9. Gilead Sciences Inc.
• 31.10. C.H. Boehringer Sohn AG & Ko. KG
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Mylan N.V.
• 31.13. Daiichi Sankyo Company Limited
• 31.14. Fresenius Kabi AG
• 31.15. Sun Pharmaceuticals LLC

32. Global Anti-Hypertensive Drugs Market Competitive Benchmarking

33. Global Anti-Hypertensive Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Anti-Hypertensive Drugs Market

35. Anti-Hypertensive Drugs Market Future Outlook and Potential Analysis

• 35.1 Anti-Hypertensive Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Anti-Hypertensive Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Anti-Hypertensive Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer